Biotechnology company ReiThera Srl reported on Tuesday that its ongoing Phase 1 study of its vaccine candidate (GRAd-COV2) against the novel coronavirus (SARS-CoV-2) is advancing on schedule.
Designed and is run jointly with the Lazzaro Spallanzani National Institute for Infectious Diseases (INMI) in Rome (Italy), this study received financial support from the Italian Ministry of Scientific Research and the Lazio Region (Rome).
Dosing and initial evaluation on the first cohort of healthy volunteers, aged between 18 and 55 years, have been completed. The company said preliminary results from this cohort, which was divided into three study arms of 15 subjects, have shown that GRAd-COV2 was well-tolerated and generated spike-binding antibodies and T-cell responses at all three doses tested.
ReiThera stated that the trial is now advancing to investigate GRAd-COV2 in the second set of three cohorts of healthy, elderly subjects, aged between 65 and 85 years. It added that results from the trial are expected to enable the selection of a vaccine dose for further investigation in a Phase 2/3 trial.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study